retatrutide phase 3 trials results for have been released, and the data are generating a lot of discussion in obesity medicine. TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and followed participants for Lilly's triple agonist, retatrutide, delivered
Description
Between 20%-50% of weight lost on GLP-1 drugs is muscle loss
It's Already a Hit Plus, the early reviews say it all
Learn whether semaglutide or tirzepatide could be a safe, effective option for you through a short medical assessment
Why Are Researchers Interested in Retatrutide
These medications influence appetite signals in the brain as well as digestion and blood sugar regulation
These results already beat many other weight loss medications available today
